Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.43
+0.7%
$1.57
$1.03
$8.64
$44.61M-0.32521,320 shs34,392 shs
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$1.23
+2.1%
$1.42
$0.77
$8.65
$223.40M0.736.33 million shs946,495 shs
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
$3.64
+0.1%
$3.94
$2.90
$6.82
$155.83M1.17100,075 shs4,169 shs
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$5.13
+7.0%
$4.21
$2.76
$6.00
$241.54M0.4115,395 shs11,337 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-1.39%+1.43%-22.40%+17.36%-80.81%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-7.34%-1.64%-29.41%+44.89%-81.07%
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
-0.55%-6.92%-12.32%+7.40%+25.17%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-5.27%+0.34%+0.76%+57.15%-13.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2.818 of 5 stars
3.45.00.00.02.50.00.6
Canopy Growth Corporation stock logo
CGC
Canopy Growth
2.8323 of 5 stars
2.53.00.00.02.80.01.3
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
0.8748 of 5 stars
3.51.00.00.00.00.00.0
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
1.6895 of 5 stars
3.33.00.00.01.10.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2.75
Moderate Buy$4.00179.72% Upside
Canopy Growth Corporation stock logo
CGC
Canopy Growth
1.00
Sell$2.0063.27% Upside
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
3.00
Buy$8.00120.08% Upside
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.0056.10% Upside

Current Analyst Ratings Breakdown

Latest ATNM, NBTX, DMAC, and CGC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
5/30/2025
Canopy Growth Corporation stock logo
CGC
Canopy Growth
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderweight ➝ Underweight
5/29/2025
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/12/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
4/28/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/A$1.31 per shareN/A
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$225.65M1.00N/AN/A$1.90 per share0.64
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
N/AN/AN/AN/A$0.95 per shareN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$39.18M6.16N/AN/A($1.51) per share-3.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M-$1.47N/AN/AN/AN/A-100.85%-47.89%N/A
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$429.86M-$4.04N/AN/AN/A-195.76%-88.54%-40.78%8/8/2025 (Estimated)
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
-$24.44M-$0.64N/AN/AN/AN/A-61.35%-55.53%8/6/2025 (Estimated)
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$73.73MN/A0.00N/AN/AN/AN/AN/A9/16/2025 (Estimated)

Latest ATNM, NBTX, DMAC, and CGC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q4 2025
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$0.28-$0.94-$0.66-$1.00$71.84 million$45.30 million
5/13/2025Q1 2025
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
-$0.18-$0.18N/A-$0.18N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Canopy Growth Corporation stock logo
CGC
Canopy Growth
N/AN/AN/AN/AN/A
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.62
3.12
2.10
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
N/A
8.02
8.02
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.04
1.04

Institutional Ownership

CompanyInstitutional Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
3.33%
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
10.12%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%

Insider Ownership

CompanyInsider Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
6.00%
Canopy Growth Corporation stock logo
CGC
Canopy Growth
1.30%
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
7.30%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3031.20 million29.32 millionOptionable
Canopy Growth Corporation stock logo
CGC
Canopy Growth
3,150183.87 million181.48 millionOptionable
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
2042.88 million39.75 millionOptionable
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
10047.13 million45.51 millionNot Optionable

Recent News About These Companies

Nanobiotix price target lowered to $8 from $12 at Guggenheim
Nanobiotix (NBTX) Gets a Hold from UBS
Nanobiotix amends global licensing agreement with Janssen Pharmaceutica

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.43 +0.01 (+0.70%)
As of 10:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Canopy Growth stock logo

Canopy Growth NASDAQ:CGC

$1.23 +0.03 (+2.08%)
As of 10:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

DiaMedica Therapeutics stock logo

DiaMedica Therapeutics NASDAQ:DMAC

$3.64 +0.01 (+0.14%)
As of 10:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$5.12 +0.34 (+6.99%)
As of 10:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.